| Ramos Cher Foot Doctor, Psc | |
|
513 Calle Carlota Matienzo, San Juan, PR 00918-3203 | |
| (787) 392-8781 | |
| (787) 753-0958 |
| Full Name | Ramos Cher Foot Doctor, Psc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 513 Calle Carlota Matienzo, San Juan, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487947107 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 105 (Puerto Rico) | Primary |
| Provider Name | Cher K Ramos |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1083685143 PECOS PAC ID: 8729002381 Enrollment ID: I20060123000125 |
News Archive
Sangamo BioSciences, Inc. announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences (PNAS), represents a significant advancement in the development of improved, less immunogenic animal tissue as a source for transplant into humans.
Living in districts with air pollution from intense crop residue burning is a leading risk factor for acute respiratory infection, especially among children less than five years, in northern India.
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed vemurafenib (trade name: Zelboraf), a drug for the treatment of adults with a certain type of advanced melanoma.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed.
Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ramos Cher Foot Doctor, Psc 513 Calle Carlota Matienzo, San Juan, PR 00918-3203 Ph: (787) 392-8781 | Ramos Cher Foot Doctor, Psc 513 Calle Carlota Matienzo, San Juan, PR 00918-3203 Ph: (787) 392-8781 |
News Archive
Sangamo BioSciences, Inc. announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences (PNAS), represents a significant advancement in the development of improved, less immunogenic animal tissue as a source for transplant into humans.
Living in districts with air pollution from intense crop residue burning is a leading risk factor for acute respiratory infection, especially among children less than five years, in northern India.
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed vemurafenib (trade name: Zelboraf), a drug for the treatment of adults with a certain type of advanced melanoma.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed.
Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.
› Verified 5 days ago
Jvlm Medicos Csp Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 9410 Ave Los Romeros, Montehiedra Town Center (altos Cine) Suite 204, San Juan, PR 00926 Phone: 787-789-3790 | |
Dr. Cher K Ramos, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 208 Ave Ponce De Leon # 735, Ste. 808, San Juan, PR 00918 Phone: 787-754-3338 Fax: 939-338-3335 | |
Dr. Jorge E Garcia Ferreras, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 9410 Ave Los Romeros, Montehiedra Town Center Suite 204, San Juan, PR 00926 Phone: 787-473-3880 Fax: 787-789-3790 | |
Dr. Luis A Walters Marquez, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: Ave De Hostos #511, Baldrich, San Juan, PR 00918 Phone: 787-250-6493 Fax: 787-250-6493 | |
Dr. Edgardo Morales Serrano, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 400 Ave Domenech, Las Americas Professional Center Suite 306, San Juan, PR 00918 Phone: 787-975-8192 Fax: 787-975-8193 | |
Clinica Podiatrica Dr Escalona Psc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 359 Calle San Claudio # Cupey, Suite 200, San Juan, PR 00926 Phone: 787-764-8798 Fax: 787-523-0925 | |
Magadme P.s.c. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1644 Calle Tiber, Rio Piedras Heights, San Juan, PR 00926 Phone: 813-753-2273 |